Mlp Saglik Hizmetleri As Class B · BIST:MPARK
Mlp Saglik Hizmetleri As Class B — MLP Care — FY2024 Earnings Presentation
19 slides from Mlp Saglik Hizmetleri As Class B's earnings presentation, Mar 10, 2025
Slide 1: MLPCare FY 2024 Presentation
MLPCARE FY 2024 PRESENTATION M a r c h 1 0 th, 2 0 2 5
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain certain forward-looking statements concerning MLP Care’s future performance and should be considered as good faith estimates made by the Company. These forward-looking statements reflect management expectations and are based upon currently ava
Slide 3: Muharrem Usta, Chairman & CEO
MUHARREM USTA CHAIRMAN & CEO
Slide 4: 2024 Financials at a Glance
2024 Financials at a Glance Revenue EBITDA TL 39,690 m TL 10,203 m • Revenue growth supported by domestic 22% Up 22% Up private medical insurance • EBITDA growth in line with top-line despite Net Debt / the dilutive effect of new hospital additions Net Profit EBITDA TL 5,786 m to the portfolio 0.5x
Slide 5: MLP Care Continues to Grow
MLP Care Continues to Grow 2024 New Hospitals Bed Capacity Square Meters Consolidation Capacity Starting From +6.300 Bed MP İncek - Ankara 182 8.225 May, 2024 MP İzmir 143 12.500 June, 2024 10% MP Gebze - Kocaeli 100 18.000 July, 2024 MP Ataşehir – İstanbul 80 8.000 July, 2024 MP Kosova - Pristina 8
Slide 6: Burcu Öztürk, CFO
Slide 7: Revenue is up by 22% in FY 2024
Revenue is up by 22% in FY 2024 Revenue (TLm) 22.5% 39.690 32.412 13.4% 10.392 9.161 Q4 2023 Q4 2024 2023 2024 Denotes growth of Revenue vs. the same period of the last year 7
Slide 8: PMI & Top-up Insurance Lead Growth
PMI & Top-up Insurance Lead Growth FY 2024 14.6% SSI coverage allows us to reach the 9.9% 18.5% majority of Turkish population 2% 11% 14% Self pay increases via premium service offering and elective procedures PMI, Top-up & Contracted Institutions market share grows rapidly on the back of stro
Slide 9: Continued Improvement in Average Prices
Continued Improvement in Average Prices Outpatient Revenues (TLm) Inpatient Revenues (TLm) 32.6% 25.0% 19.3% 16.5% 13.3% 8.5% 2,400 2,365 1,636 1,233 16,264 18,161 15.760 12,263 14,527 14.527 2023 Volume & Mix Price 2024 2023 Volume & Mix Price 2024 Average Revenue Per Visit (ARPV) Average Revenue P
Slide 10: EBITDA Is Up By 22% in FY 2024
EBITDA Is Up By 22% in FY 2024 EBITDA (TLm)1 22.2% 25,7% 10.203 25.8% 6.5% 8.350 31.2% 25.7% 2.858 2.671 Q4 2023 Q4 2024 2023 2024 1 EBITDA and EBITDA margin calculated by deducting general administrative expenses from gross profit and adding depreciation and amortization expenses Denotes growth/dec
Slide 11: Prudent Cost Management
Prudent Cost Management Cost of Service and G&A Expenses as a % of Revenues Cost Saving Measures enables us to reach the favourable EBITDA Margin EBITDA Margin 25.8% 25.7% Material costs as a % of revenue decreased by 11.4% 9.8% 92bps due to effective inventory management 6.0% 6.1% Doctor costs
Slide 12: Net Profit Impacted by Monetary Gain/Loss
Net Profit Impacted by Monetary Gain/Loss Net Profit (TLm) Net Profit (TLm) Excluding Monetary Gain/Loss 15,6% 6.855 154.5% 5.786 4.231 1.663 2023 2024 2023 2024 Denotes growth/decrase of Net Profit and Net Profit Allocated to Equity Holders of the Parent vs. the same period of the last year 12
Slide 13: Leverage Ratio Improves
Leverage Leverage Ratio Ratio Improves Improves Total Debt Total Debt Breakdown 2024 8.743 Other; 7.989 Bank 412 Loans; 1.029 Bonds; 2.000 Lease Liabilities; 4.548 2023 2024 Net Debt Net Debt excl. IFRS 16 5.261 4.683 1.418 0.6x 0.2x 714 0.5x 0.1x 2023 2024 2023 2024 *All figures are presented in mi
Slide 14: Cash Flow
Cash Flow Operating Cash Flow increased due to million TL 2023 2024 Change strong EBITDA growth. EBITDA 8,350 10,203 1,853 Taxes paid increased due to increase in Changes in working capital 894 632 (261) corporate tax rate. Corporate tax rate Tax paid (519) (816) 297 increased from 20% to 25%. O
Slide 15: Q&A
Q&A
Slide 16: Closing Remarks
Closing Remarks MUHARREM USTA CHAIRMAN & CEO
Slide 17: Historical Balance Sheet
Historical Balance Sheet Audited Audited TLm December 31, 2024 December 31, 2023 Cash and cash equivalents 2,728 4,060 Trade receivables 6,087 5,280 Inventory 1,004 1,554 Short term other assets 1,370 1,319 Current assets 11,188 12,214 Tangible and intangible fixed assets 16,958 12,068 Right of use
Slide 18: Historical P&L Statements
Historical P&L Statements Audited Audited Change (%) TLm 2024 2023 Revenues 39,690 32,412 22.5% Cost of service (-) (28,831) (23,128) 24.7% Gross profit 10,859 9,284 17.0% General administration expenses (-) (3,367) (3,160) 6.5% Other income from operations 781 1,376 (43.3%) Other expenses from oper
Slide 19: EBITDA Reconciliation
EBITDA Reconciliation TLm 2024 2023 Change (%) Revenue 39,690 32,412 22.5% Cost of service (28,831) (23,128) 24.7% Gross profit 10,859 9,284 17.0% General administrative expenses (-) (3,367) (3,160) 6.5% Depreciation and amortization expenses (Cost of service) 3,367 2,028 24.6% Depreciation and amor